Vinorelbine
Links shared publicly online about this topic
Vinorelbine Tartrate - National Cancer Institute
cancer.gov — “This page contains brief information about vinorelbine tartrate and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.” View full resource at cancer.gov
Most Recently Shared on June 3, 2011 at 5:58 pm By:
NCI Cancer Bulletin Health News
New from cancer.gov: Drug information summary for vinorelbine tartrate in non-small cell lung cancer http://1.usa.gov/jystmD
Cutaneous Recall Phenomenon with Vinorelbine (September)
theannals.com — “Cutaneous Recall Phenomenon with Vinorelbine (September)” View full resource at theannals.com
Most Recently Shared on August 24, 2011 at 4:45 am By:
Cutaneous Recall Phenomenon with Vinorelbine (September): http://t.co/AmScgol
Oncology Medical News about Prostatic Neoplasms Paclitaxel vinorelbine
mdlinx.com — “Phase II study of paclitaxel and vinorelbine (Pacl-Vin) in hormone-refractory metastatic prostate cancer: double tubulin targeting” View full resource at mdlinx.com
Most Recently Shared on March 22, 2010 at 9:07 am By:
Sandeep Pulim MD Doctor, Health Communicator, and Physician
Phase II study of paclitaxel and vinorelbine (Pacl-Vin) in hormone-refractory metastatic prostate cancer: ... http://bit.ly/a2RJZM #HemeOnc
Vinorelbine 'Preferred' Chemo in HER2-Positive Advanced Breast Cancer - QualityPoint Technologies
qualitypointtech.net — “Vinorelbine is not more effective than a taxane, according to a new phase 3 study, but it does have a better toxicity profile. Medscape Medical News” View full resource at qualitypointtech.net
Most Recently Shared on January 26, 2011 at 4:01 pm By:
Vinorelbine 'Preferred' Chemo in HER2-Positive Advanced Breast Cancer: Vinorelbine is not more effective than a ... http://bit.ly/f3an2j
Dose Escalation of Once Weekly Oral Vinorelbine Co... [Am J Med Sci. 2011] - PubMed result
ncbi.nlm.nih.gov — “PubMed is a service of the U.S. National Library of Medicine that includes over 19 million citations from MEDLINE and other life science journals for biomedical articles back to the 1950s. PubMed includes links to full text articles and other related resources.” View full resource at ncbi.nlm.nih.gov
Most Recently Shared on June 1, 2011 at 11:16 am By:
Dose Escalation of Once Weekly Oral Vinorelbine Concurrent With Weekly Split Dose Hypofractionated Chest Radiati... http://bit.ly/muNXnh
Rituximab + Vinorelbine, Ifosfamide, Mitoxantrone, and Prednisone: A Suitable Salvage Treatment for Patients With Relapsed Diffuse Large B-Cell Lymphoma - ONA
oncologynurseadvisor.com — “The combination of rituximab plus vinorelbine, ifosfamide, mitoxantrone, and prednisone (R-NIMP) is well tolerated, yields a high complete response rate, and allows for successful mobilization of CD34+ cells in patients with diffuse large B-cell lymphoma (DLBCL) in first relapse, results of a phase 2 study presented at the 52nd American Society of Hematology Annual Meeting and Exposition have found.” View full resource at oncologynurseadvisor.com
Most Recently Shared on December 6, 2010 at 4:05 pm By:
OncologyNurseAdvisor Oncology, Nursing, Medical Education, and Medical Publisher
Rituximab + Vinorelbine, Ifosfamide, Mitoxantrone, and Prednisone: A Suitable Salvage… http://goo.gl/fb/YCMoS
Phase II trial of single-agent oral vinorelbine in elderly (70 years) patients with advanced non-small-cell lung cancer and poor performance status " Ann Oncol
annonc.oxfordjournals.org — “Phase II trial of single-agent oral vinorelbine in elderly (70 years) patients with advanced non-small-cell lung cancer and poor performance status " Ann Oncol” View full resource at annonc.oxfordjournals.org
Most Recently Shared on May 25, 2010 at 8:45 pm By:
Phase II trial of single-agent oral vinorelbine in elderly (>=70 years) patients with advanced non-small-cell lung... http://bit.ly/bE1vi
Study of RAD001 in Patients With Relapsed/Refractory Hodgkin Lymphoma That Has Progressed After High-dose Chemotherapy and Autologous Stem Cell Transplant and/or After Gemcitabine- or Vinorelbine- or Vinblastine-based Treatment. - Full Text View - Clinica
clinicaltrials.gov — “Study of RAD001 in Patients With Relapsed/Refractory Hodgkin Lymphoma That Has Progressed After High-dose Chemotherapy and Autologous Stem Cell Transplant and/or After Gemcitabine- or Vinorelbine- or Vinblastine-based Treatment. - Full Text View - ClinicalTrials.gov” View full resource at clinicaltrials.gov
Most Recently Shared on January 8, 2010 at 3:46 am By:
Trial for refractory Hodgkin Lymphoma pts at Mayo Clinic. http://bit.ly/4MRM8A
Economic evaluation of docetaxel"gemcitabine versus vinorelbine"cisplatin combination as front-line treatment of patients with advanced/metastatic non-small-cell lung cancer in Greece: a cost-minimization analysis " Ann Oncol
annonc.oxfordjournals.org — “Economic evaluation of docetaxel"gemcitabine versus vinorelbine"cisplatin combination as front-line treatment of patients with advanced/metastatic non-small-cell lung cancer in Greece: a cost-minimization analysis " Ann Oncol” View full resource at annonc.oxfordjournals.org
Most Recently Shared on June 24, 2010 at 9:51 am By:
Economic evaluation of docetaxel-gemcitabine versus vinorelbine-cisplatin combination as front-line treatment of p... http://bit.ly/d7cMJx
Adventrx Announces 12-Month Stability Data Results for ANX-530 - Drugs.com MedNews
drugs.com — “ADVENTRX Pharmaceuticals, Inc. (NYSE Amex ANX) today announced the results of stability tests performed on samples of ANX-530 (vinorelbine injectable emulsion),” View full resource at drugs.com
Most Recently Shared on September 14, 2010 at 1:08 pm By:
Drugs and Devices OW OW Health
Adventrx Announces 12-Month Stability Data Results for ANX-530: SAN DIEGO, Sept. 14 /PRNewswire/ -- ADVENTRX ... http://bit.ly/b1Lz9E #drug
FDA Accepts Exelbine NDA for Filing
drugs.com — “xelbine (vinorelbine injectable emulsion) is a new drug formulation in development for the treatment of non-small cell lung cancer. Exelbine information includes news, clinical trial results and side effects.” View full resource at drugs.com
Most Recently Shared on January 9, 2011 at 7:12 am By:
Drugs and Devices OW OW Health
FDA Accepts Exelbine NDA for Filing: SAN DIEGO, Jan. 6, 2011 /PRNewswire/ -- Adventrx Pharmaceuticals, Inc... http://bit.ly/dH3yq8 #drug
Treatment of Peripheral T-cell Lymphoma With Aggressive Induction Chemotherapy Followed by Autologous Stem Cell Transplant Using Denileukin Diftitox (Ontak) - Full Text View - ClinicalTrials.gov
clinicaltrials.gov — “Treatment of Peripheral T-cell Lymphoma With Aggressive Induction Chemotherapy Followed by Autologous Stem Cell Transplant Using Denileukin Diftitox (Ontak) - Full Text View - ClinicalTrials.gov” View full resource at clinicaltrials.gov
Most Recently Shared on January 15, 2010 at 11:12 pm By:
Multi-Center Clinical Trial for T-Cell w/ SCT. Download, print, discuss w/ your onc to see appropriate. http://bit.ly/52PjCg
FDA Accepts Exelbine™ NDA For Filing
medicalnewstoday.com — “ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX) announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the New Drug Application (NDA) for its product candidate ANX-530” View full resource at medicalnewstoday.com
Most Recently Shared on January 7, 2011 at 2:05 pm By:
FDA Accepts Exelbine™ NDA For Filing http://mnt.to/3PJW #lungcancer
First-cycle rash and survival in patients with advanced non-small-cell lung cancer receiving cetuximab in combination with first-line chemotherapy: a subgroup analysis of data from the FLEX phase 3 study : The Lancet Oncology
thelancet.com — “First-cycle rash and survival in patients with advanced non-small-cell lung cancer receiving cetuximab in combination with first-line chemotherapy: a subgroup analysis of data from the FLEX phase 3...” View full resource at thelancet.com
Most Recently Shared on January 1, 2011 at 7:17 pm By:
[Articles] First-cycle rash and survival in patients with advanced non-small-cell lung cancer receiving cetuxima... http://bit.ly/hq1bIG
Oncology Article | Lymphoma
mdlinx.com — “Gemcitabine and vinorelbine combination is effective in both as a salvage and mobilization regimen in relapsed or refractory Hodgkin lymphoma prior to ASCT” View full resource at mdlinx.com
Most Recently Shared on December 3, 2010 at 2:27 pm By:
Sandeep Pulim MD Doctor, Health Communicator, and Physician
Gemcitabine and vinorelbine combination is effective in both as a salvage and mobilization regimen in ... http://bit.ly/fJmp12 #oncology
The Top 3 resources shared on this topic. More resources.
Key stats and trends about this topic
Related WisdomCards
Featuring the top 3 experts for this topic
-
NCI Cancer Bulletin
Cancer research news and information from the news staff of the NCI Cancer Bulletin. Tweets by Carmen Phillips and Edward Winstead
-
The Annals
The Annals of Pharmacotherapy is a peer-reviewed medical journal advancing drug therapy by publishing evidence-based pharmacy research and clinical reviews.
-
Sandeep Pulim MD
Over 2K medical journal articles & health news summarized and delivered FREE to 35 specialties daily. Oncology, Rheumatology, Cardiology, Neurology, Psychiatry
Advertisement
